Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare disorder characterized by vascular proliferation, eosinophilia in peripheral blood samples and lymphocytosis. The etiology is unknown; this rare condition is generally seen in women. It often presents as multiple, grouped red nodules in the periauricular region, scalp line and neck. Numerous therapeutic approaches have been tried for ALHE including destructive techniques such as electrodesiccation, cryotherapy, surgical excision, radiotherapy or laser (argon, CO2, pulse dye). We present an ALHE case that was treated successfully by using topical imiquimod cream.

Keywords:
Angiolymphoid hyperplasia with eosinophilia, Imiquimod
1.
Requena L, Sangueza OP: Cutaneous vascular proliferation. 2. Hyperplasias and benign neoplasms. J Am Acad Dermatol 1997;37:887–920.
2.
Conill C, Toscas I, Mascaro JM Jr, Vilalta A, Mascaro JM: Angiolymphoid hyperplasia with eosinophilia of the nail bed and bone: successfully treated with radiation therapy. J EADV 2004;18:584.
3.
Sidbury R, Neuschler E, et al: Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205–1209.
4.
Sanchez-Carpintero I, Martinez MI, Mihm MC Jr: Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget’s mammary disease. J Am Acad Dermatol 2006;55:75–79.
5.
Yan J, Chen SL, Wang HN, Wu TX: Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006;213:218– 223.
6.
Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr: Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881–884.
7.
Hazen PG, Carney JF, Engstrom CW, Turgeon KL, Reep MD, Tanphaichitr A: Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005;22:254–256.
8.
Welsh O, Olazaran Z, Gomez M, Salas J, Berman B: Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004;51:639–642.
9.
Redondo P, Olmo JD, Idoate M: Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. Br J Dermatol 2004;151:1110.
10.
Azizzadeh M, Namazi MR, Dastghaib L, Sari-Aslani F: Angiolymphoid hyperplasia with eosinophilia and nephrotic syndrome. Int J Dermatol 2005;44:242.
11.
Helander SD, Peters MS, Kuo TT, Su WP: Kimura’s disease and angiolymphoid hyperplasia with eosinophilia: new observations from immunohistochemical studies of lymphocyte markers, endothelial antigens and granulocyte proteins. J Cutan Pathol 1995;22:319–326.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.